TVRD Tvardi Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1346830 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.7%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-123.1%
ROA-85.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets34.3%
Debt / equity0.00x
Current ratio2.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $7.14M |
| R&D expense | $18.01M | $23.65M |
| SG&A expense | $8.74M | $4.46M |
| Operating income | -$26.75M | -$28.11M |
| Pretax income | — | -$71.27M |
| Income tax | $0 | $0 |
| Net income | -$18.21M | -$29.40M |
| EBITDA | -$26.65M | -$28.01M |
| EPS (basic) | -2.46 | -11.42 |
| EPS (diluted) | -3.26 | -11.42 |
| Dividends declared per share | 0.00 | — |
| Weighted avg. shares (diluted) | 7.78M | 2.57M |
| Balance sheet | ||
| Cash & equivalents | $20.73M | $31.61M |
| Short-term investments | $10.08M | — |
| Receivables | — | $407,000 |
| Inventory | — | $900,000 |
| Current assets | $31.54M | $31.69M |
| PP&E, net | $52,000 | $84,000 |
| Intangibles | $322,000 | $385,000 |
| Total assets | $32.07M | $35.20M |
| Current liabilities | $11.04M | $10.37M |
| Total liabilities | $11.13M | $40.83M |
| Shareholders' equity | $20.95M | -$91.13M |
| Shares outstanding | 9.38M | 2.57M |
| Cash flow statement | ||
| Operating cash flow | -$23.50M | -$18.30M |
| Capital expenditure | — | $1.05M |
| Free cash flow | — | -$19.35M |
| Investing cash flow | -$10.08M | $48.74M |
| Financing cash flow | $22.70M | $27.00M |
| Depreciation & amortization | $95,000 | $95,000 |
| Stock-based compensation | $1.40M | $319,000 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.